If You Invested in Waters (WAT)

Waters Corporation (NYSE: WAT) is a global company in the field of analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences. According to the company, it has been active in these markets for over 65 years and works with customers in more than 100 countries. Waters’ technologies help support the efficacy of medicines, the safety of food, the purity of water, and the quality and sustainability of products used every day.

Waters is associated with the analytical laboratory instrument manufacturing industry and the broader manufacturing sector. The company’s analytical tools and separations technologies are used in laboratories, manufacturing sites, and hospitals, where scientists and technicians analyze molecular structures and physical properties of a wide range of materials. Waters states that its employees collaborate with customers to accelerate the benefits of pioneering science across regulated and research-intensive environments.

Business focus and customer segments

Waters describes itself as a global leader in analytical instruments and separations technologies, with a significant software business. Its technologies are used across life sciences, materials science, food science, and environmental science applications. The company highlights that its solutions are used to help ensure that medicines work as intended, food products meet safety standards, and water supplies meet purity requirements.

Based on the available information, Waters serves multiple customer segments, including biopharmaceutical companies, industrial clients, and academic and government institutions. The Polygon description notes that Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools, which provide essential information on products such as molecular structures and physical properties. These tools are used to help clients enhance the health and well-being of end users.

Technologies and products

Waters’ portfolio includes analytical instruments and software platforms used in chromatography and mass spectrometry workflows. The company reports that it is a global leader in chromatography software solutions for regulatory filings through its Empower Chromatography Data System (CDS), which it describes as the world’s most trusted chromatography data system. Internal analysis cited by Waters indicates that Empower Software is used to submit data for a large share of novel drugs to regulatory authorities.

In its news releases, Waters has highlighted product developments such as a Charged Aerosol Detector (CAD) designed for use with Empower Software. This detector is described as delivering sensitive, consistent, and reproducible measurement of analytes with little or no UV absorption, and is positioned for use in pharmaceutical formulations, food additives, nutrients, and environmental pollutants. Waters states that the detector integrates with a range of its liquid chromatography systems and is intended to improve communication reliability and workflow efficiency in quality control and development environments.

Waters has also announced the Xevo Charge Detection Mass Spectrometer (CDMS), which it describes as a system for measuring and characterizing large, heterogeneous biomolecules relevant to next-generation therapeutics and structural biology. According to the company’s description, the Xevo CDMS enables direct, individual-particle mass measurement for very large molecules and is intended to support applications in areas such as cell and gene therapies, mRNA, and complex protein therapeutics.

Role in regulated and scientific markets

The company’s communications emphasize that Waters’ technologies are used in regulated environments and in high-volume testing contexts. Its instruments and software support workflows across discovery, development, quality control, and manufacturing. In particular, Waters points to the use of its chromatography and mass spectrometry systems, along with its informatics platforms, in pharmaceutical and biopharmaceutical applications, as well as in food and environmental testing.

Waters also highlights its involvement in bioanalytical characterization and bioseparations. In its financial and transaction-related disclosures, the company notes that it is expanding into adjacent end markets such as bioseparations, bioanalytical characterization, and multiplex diagnostics. These areas build on Waters’ expertise in separations technologies, chemistry, and downstream high-volume applications.

Strategic combination with BD’s Biosciences & Diagnostic Solutions business

Waters has entered into definitive agreements with Becton, Dickinson and Company (BD) and Augusta SpinCo Corporation for a Reverse Morris Trust transaction. Under these agreements, BD will separate its Biosciences and Diagnostic Solutions business into SpinCo, distribute SpinCo shares to BD shareholders, and then SpinCo will merge with a subsidiary of Waters. When the merger is completed, SpinCo will become a wholly owned subsidiary of Waters, and former BD shareholders will own a significant minority of the combined company’s shares, with existing Waters shareholders owning the remainder, as described in the company’s Form 8-K filings.

Waters and BD describe this planned combination as bringing together complementary technologies in liquid chromatography, mass spectrometry, flow cytometry, and diagnostic solutions, with a focus on regulated, high-volume testing in clinical and life science markets. The companies state that the transaction is intended to expand Waters’ presence in adjacencies such as bioseparations, bioanalytical characterization, and multiplex diagnostics, and to increase the proportion of recurring revenue. The transaction remains subject to regulatory approvals, shareholder approval, and other customary closing conditions, and the parties have outlined tax, employee, intellectual property, transition services, and manufacturing arrangements in their agreements.

Global footprint and workforce

Waters reports that it has more than 7,600 employees and operations in over 100 countries. Its employees work with customers in laboratories, manufacturing sites, and hospitals. The company positions this global presence as a way to collaborate closely with customers on scientific and analytical challenges across different regions and regulatory environments.

Stock information and regulatory reporting

Waters Corporation’s common stock trades on the New York Stock Exchange under the ticker symbol WAT, as indicated in its Form 8-K filings. The company files periodic and current reports, including Forms 10-K, 10-Q, and 8-K, with the U.S. Securities and Exchange Commission (SEC). These filings provide information on its financial performance, material agreements, and significant corporate transactions, such as the planned combination with BD’s Biosciences and Diagnostic Solutions business.

Use cases and impact

According to Waters’ public descriptions, its technologies are used to support a wide variety of scientific and industrial use cases. In pharmaceuticals and biopharmaceuticals, Waters’ instruments and software are used to characterize drug substances and products, monitor impurities, and support regulatory submissions. In food and environmental applications, its systems help measure contaminants, additives, and other analytes relevant to safety and regulatory standards. In materials science and other industrial contexts, Waters’ analytical tools are used to understand material properties and performance.

The company emphasizes that its work contributes to outcomes such as effective medicines, safe food, pure water, and sustainable products. By providing analytical instruments, separations technologies, and software, Waters aims to support customers in regulated and research-intensive sectors where accurate, reproducible measurements are critical.

Future direction as described by the company

In its communications and transaction-related disclosures, Waters describes a strategy focused on commercial execution, product innovation, and expansion into adjacent markets. The planned combination with BD’s Biosciences and Diagnostic Solutions business is presented by the company as a way to increase its exposure to high-growth end markets and to apply its execution model to a broader set of technologies and customer segments. The company’s news releases also highlight ongoing investment in new instruments and detectors, as well as enhancements to its software platforms, to address evolving analytical needs in life sciences, food, environmental, and materials applications.